The Castleman disease is a rare and often deadly disorder affecting lymph nodes and related tissues. It is named after Dr. Benjamin Castleman, who first described the disease in 1954.

The Castleman disease is a complex and poorly understood disease which can affect various organs of the body. While different forms of Castleman disease can manifest differently, all share a common thread of causing a buildup of cells in lymph nodes.

Castleman disease is a heterogenous group of diseases, characterized by the growth of excessive lymphoid tissue that can exhibit either hyaline vascular (HV) [also known as plasma cell type] or plasma cell (PC) features [also known as multicentric Castleman disease (MCD)]; this excessive growth can cause various symptoms such as fever, fatigue, night sweats, loss of appetite and weight loss, enlarged lymph nodes, enlarged liver and spleen, and neurological symptoms amongst others. The exact cause of Castleman disease is unknown, but it is believed to occur when the immune system mistakenly attacks healthy tissue.

World Castleman Day is observed globally to raise awareness about this rare and complicated disorder.

It is celebrated on the last Wednesday of July every year since the inaugural event held on July 31, 2019, as a collaborative initiative of the Castleman Disease Collaborative Network (CDCN) and the global legion of clinicians, researchers, advocates, and others working tirelessly to advance research, raise awareness, and support patients and families affected by Castleman disease. World Castleman Day provides a unique opportunity to highlight the significant work done to improve patient outcomes, promote collaborations, and to educate the public about this disease.

Objectives of World Castleman Day

The main objective of World Castleman Day is to raise awareness of the Castleman disease and encourage the exchange of knowledge between scientists, patients, medical professionals, and other relevant stakeholders.

The day aims to highlight the importance of early diagnosis, excellent medical care for patients, adequate support, and investment in research to help increase understanding of Castleman disease’s etiology, pathogenesis, and treatment.

Understanding The Different Types of Castleman Disease

The two main types of Castleman disease are Unicentric Castleman disease (UCD) and Multicentric Castleman Disease (MCD). UCD is the less common of the two types and symptoms usually include a localized swelling or mass that may cause pain or discomfort.

MCD, on the other hand, can have life-threatening complications such as multiple organ failure. The hyaline vascular (HV) subtype is the most common histological type of unicentric Castleman Disease, affecting a single lymph node station, most commonly in the chest, neck or abdomen.

The form of MCD with PC features is characterized by the presence of enlarged lymph nodes, often accompanied by systemic symptoms such as fever, sweats, and weight loss and it can progress to life-threatening symptoms like organ failure.

The Importance of Awareness and Research

Castleman disease is a rare disease and can be challenging to diagnose as it can sometimes mimic other illnesses.

It is estimated that there are fewer than 5,000 people in the United States who suffer from the disease; however, the true prevalence is unknown. Awareness is critical to ensure early diagnosis, optimal management, and improved treatment outcomes.

World Castleman Day helps to raise awareness about the disease, educating the public and medical professionals, and encouraging collaboration towards discovering new treatment options.

There is currently no cure for Castleman disease, and treatment approaches vary depending on the subtype, severity of the symptoms, and patient characteristics.

The treatments available today for Castleman disease are not always adequate in managing the disease, with indications of high relapse rates following treatment cessation. Therefore investing in research to understand Castleman disease’s pathological mechanism is now as impornt as never before.

The research can help clinicians and scientists generate new approaches to treating the disease that could potentially improve the prognosis considerably. Research studies like the CDCN’s ACCELERATE registry are among such initiatives that could help drive research collaborations that can lead to groundbreaking discoveries.

Supporting Castleman Disease Research

Philanthropic support is critical to advocacy organizations that lead the way for Castleman disease research.

Groups like the CDCN, which has a mission to accelerate research, treatment, and patient care of Castleman disease, depend mainly on donations to carry out their critical research work, patient support, and advocacy activities. There is no better way to contribute to this remarkable initiative than financial contributions directed explicitly toward Castleman disease research, patient support, and advocacy activities.

Conclusion

World Castleman day is a vital event that shines a light on a rare and complex disease that affects a small but growing number of people worldwide.

It is a collaborative initiative between individuals, organizations, and advocacy groups to promote awareness, support, research, and better patient outcomes. Through continued investment in Castleman disease research, collaborations, and advocacies, there is a renewed sense of hope that a cure may one day be found for this potentially life-threatening disorder.